Therapeutic Experience
We help our customers conduct cost-efficient observational studies worldwide
Along with clinical specialists, our team of epidemiologists, statisticians, clinicians, health economists and qualitative researchers conduct effective field, secondary data and hybrid observational studies to achieve our client’s goals.
OXON offers proven experience and a large portfolio of studies in all major therapy areas, orphan conditions, pregnancy and risk minimization, combining clinical, epidemiological and statistical expertise particularly in the areas of oncology, neuroscience, cardio metabolic and COVID-19.
Our Core Therapeutic Areas expertise
Metabolic
OXON has working experience on:
• Diabetes
• Osteoporosis
• Gout
We have worked on a pragmatic trial of a Gliflozin (SGLT2i).
We receive scientific consultation from Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine, who is an international leader in diabetes trials and registries.
Cardiovascular
Our staff have worked on studies in Obesity, High blood pressure, Lipids, Anti-coagulants, Anti-thrombotic and Heart failure, having completed studies with cardiovascular and Stroke safety endpoints. Several of these projects have led to full publications in The Lancet, with OXON authors.
Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine, who is an international leader in cardiovascular trials and registries and evaluation of Cardiovascular safety issues, consults us in this field.
Oncology
OXON has worked on studies in solid cancers: Lung, Breast, Colorectal, Urothelial, Melanoma, and Haematologic cancers: Multiple myeloma and Leukaemia, Oncologic pain.
We can analyse the Systemic Anti-Cancer Therapy (SACT) database in the UK.
We work together with Clinical oncologists and Haematologists with whom we consult closely.
Neuroscience
OXON has worked on studies in Alzheimer’s disease and other dementias, Parkinson’s disease, Multiple sclerosis, Epilepsy, Schizophrenia, Anti-Psychotics, Anti-depressants, with one publication in The Lancet, among others.
One of our senior clinical epidemiologists is chief author of the international textbook: ´Evidence-based Dementia Practice´, Published by Wiley-Blackwells, Oxford and was Founding Editor of the Cochrane Dementia Group.
Orphan
OXON has worked on a wide range of rare diseases such as studies in Fabry, Gaucher, Pompe, and Spinal Muscular Atrophy. These studies include many different approaches, with emphasis on the use of ultra-rare orphan disease registries.
Immunology
We have worked on studies in Rheumatoid Arthritis, Atopic Dermatitis, Psoriasis, Organ Transplant Rejection, and other medical conditions from an immunologic point of view. We have recently successfully finalised a PAS Evaluation study in Transplant Rejection.
Vaccines
OXON has worked on studies in Influenza, Pneumococcal Disease, Diphtheria-Tetanus-Pertussis, Rotavirus, and Herpes Zoster. Our experience in this field does not only cover PASS studies, but also feasibility assessments and the use of databases in several European countries.
Respiratory
Our motivation in the clinical respiratory field has promoted innovative approaches in feasibility studies, as well as other types of studies related to COPD, Asthma and Allergic Bronchopulmonary Aspergillosis.
Gastroenterology
OXON has worked on studies in Inflammatory Bowel Disease, Liver Disease, Peptic Ulcer, Laxatives, etc. We are currently working on a study that requires strategic skills and experience with PASS studies.
Ophthalmology
We have experience in studies in Keratoconjunctivitis.
Paediatrics
We have worked on several studies involving children: Vaccines, Leukaemia, Rotavirus, and others. We have experience in adapting the study and study documentation such as parental consent and children’s assent forms to the appropriate age group and ensure achievement of the objectives.
Pregnancy
OXON has developed a novel approach to studying drug exposure during pregnancy, with a follow up on pregnancy, birth, infant and childhood outcomes with the use of prospective pregnancy registries and hybrid database approaches.